Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FERMT2 siRNA
- Development stage
- Preclinical
- Lead developer
- National Taiwan University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intrathecal, Intravenous
01
Overview
FERMT2 siRNA is a small interfering RNA designed to silence the expression of Fermitin family member 2 (FERMT2), also known as Kindlin-2. In the context of esophageal squamous cell carcinoma (ESCC), FERMT2 has been identified as a target of miR-338-5p. Silencing FERMT2 using siRNA has been shown in preclinical studies to inhibit cancer cell proliferation, migration, and colony formation. Furthermore, FERMT2 knockdown enhances the sensitivity of ESCC cells to cisplatin-induced cytotoxicity, suggesting its potential as a therapeutic target to overcome chemoresistance.
- Other names
- si-FERMT2si-FERMT-2si-FERMT 2FERMT2 small interfering RNAFERMT-2 small interfering RNAFERMT 2 small interfering RNA
02
Targets
FERMT2 (Fermitin family member 2)
Beyond the preview
Go deeper on FERMT2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FERMT2 siRNA.